This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Pluristem Completes Enrollment For Phase I/II Muscle Injury Trial

HAIFA, Israel, July 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has completed the target enrollment in a randomized, double-blinded, placebo controlled Phase I/II clinical trial to assess the safety and efficacy of its PLacental Expanded (PLX) cells for the treatment of traumatized muscles. All patients have been treated with PLX-PAD cells or placebo and are currently in the follow up stage of the trial.

The study is being conducted at the Orthopedic Clinic on the campus of the Charité University Medical School in Berlin, Germany and is under the oversight of Germany's healthcare regulatory bodies, the Paul Ehrlich Institute (PEI) and Berlin's Ethic Committee, LaGeSo.

In this trial patients were injected with either PLX-PAD cells or placebo directly into their gluteal muscles that had been surgically traumatized during hip replacement surgery. The primary endpoint of the study is to assess the safety and efficacy of PLX-PAD cells in evaluating the rehabilitation of the muscle activity of the patient at six months following treatment. Secondary efficacy endpoints include Magnetic Resonance Imaging (MRI) and macroscopic and microscopic structure of the involved gluteal muscles from biopsies taken at three months post therapy (Reference: http://clinicaltrials.gov/ct2/show/NCT01525667?term=pluristem&rank=3 ).

"Having treated all patients in this trial, we have reached a milestone. The ease of use of our allogeneic, off-the-shelf product enabled us to complete recruitment quickly and efficiently. Following completion of the follow up period, we will obtain data on the safety and efficacy of PLX-PAD cells in the treatment of traumatized muscles during hip replacement surgery" stated Zami Aberman, Chairman and CEO of Pluristem. "This trial is important as it marks the first time PLX-PAD cells have been used in patients following surgically induced muscle trauma. It also provides data on the potential use of PLX cells for the treatment of sports related injuries."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs